Lion Point Capital’s Atara Biotherapeutics ATRA Stock Holding History

Lion Point Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,019	Closed	-$6.27M	–	34
2021 Q3	$6.27M	Buy	+14,019	New	+$5.02M	1.18%	20

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lion Point Capital's ATRA Position: Q4 2021 in Review

Lion Point Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2021, closing a stake of 14,019 shares — an estimated $6.27M sold.

Lion Point Capital first reported a position in ATRA in Q3 2021 and held it in 1 quarter. The position peaked at $6.27M in Q3 2021. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2021.

Lion Point Capital reported no remaining Atara Biotherapeutics position as of Q4 2021 after selling out during the quarter.
Lion Point Capital sold 14,019 Atara Biotherapeutics shares in Q4 2021, an estimated $6.27M.
Lion Point Capital first reported a position in Atara Biotherapeutics in Q3 2021 and held it in 1 quarter.
Lion Point Capital's Atara Biotherapeutics position peaked at $6.27M in Q3 2021.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2021.

Based on Lion Point Capital's 13F filing for Q4 2021, filed 14 Feb 2022.